98%
921
2 minutes
20
Objective: This study aimed to validate the real-world performance of the MyIUS mobile-application algorithm in predicting bleeding intensity and regularity in levonorgestrel intrauterine device (LNG-IUD) 52 mg, 19.5 mg, and 13.5 mg users following device insertion.
Study Design: This was an observational real-world performance study conducted in Germany, Denmark, Sweden, Spain, Mexico, and Brazil, including women aged ≥18 who provided electronic written informed consent and had used the MyIUS app for 90 days following LNG-IUD 52 mg, 19.5 mg, or 13.5 mg insertion. At day 90, participants received personalized bleeding predictions for one of three bleeding intensity clusters (predominantly amenorrhea, predominantly spotting, or predominantly bleeding), with those predicted predominantly spotting or predominantly bleeding receiving regular or irregular cycle predictions. After the 270-day data collection period, bleeding data self-reported from the last 180 days were evaluated and compared with the bleeding profile prediction.
Results: Based on 1,734 participants with close-to-complete datasets, the overall multiclass area under the curve (AUC) for the three LNG-IUDs was 0.81 (95% confidence interval [CI], 0.79-0.83) for bleeding intensity prediction, corresponding to sufficient discrimination in algorithm performance based on predefined thresholds. The overall AUC for menstrual cycle regularity prediction was 0.66 (95% CI, 0.63-0.68).
Conclusion: Results validated the bleeding intensity prediction algorithm in a real-world environment, providing evidence to support the global use of MyIUS for individualized insights into bleeding changes following LNG-IUD insertion. Further refinement of the algorithm, especially regarding its performance in predicting cycle regularity, and testing of its clinical utility are warranted.
Implications: This study validated the mobile application-housed bleeding prediction algorithm MyIUS in predicting bleeding intensity in levonorgestrel intrauterine device (LNG-IUD) users following insertion in a real-world setting, supporting the global use of MyIUS for individualized insights into bleeding changes following LNG-IUD insertion.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.contraception.2025.111201 | DOI Listing |
Cardiol Rev
September 2025
Departments of Cardiology and Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY.
Arteriovenous malformations (AVMs) are abnormal connections between cerebral arteries and veins that lack an intervening capillary bed. Brain AVMs affect approximately 0.1% of the population and are diagnosed in 1.
View Article and Find Full Text PDFInt J Gynaecol Obstet
September 2025
Department of Gynecology and Obstetrics, Justus Liebig University Giessen, Giessen, Germany.
Even though uterine fibroids are a widespread condition, the range of approved medical treatment options remains limited. In fact, only a few drugs are officially approved for the therapy of fibroids. In both the USA and the European Medicines Agency region, selected gonadotropin-releasing hormone (GnRH) antagonists have been approved for this indication.
View Article and Find Full Text PDFMedicine (Baltimore)
September 2025
Suzuki Proctology-Moriguchi Internal Medicine Clinic, Morioka, Iwate, Japan.
Rationale: Prolapsed hemorrhoids can impair quality of life due to associated symptoms such as pain. While hemorrhoidectomy is considered the gold standard for treating prolapsed hemorrhoids, this procedure inevitably involves complications such as postoperative pain, bleeding, and delayed recovery. Therefore, there is an increasing need for treatment options that are immediate, effective, and minimally invasive, while also taking into account patients' physical and social backgrounds, preferences, and values.
View Article and Find Full Text PDFJ Thromb Haemost
September 2025
Department of Medicine and Ageing Sciences, Gabriele D'Annunzio University, Chieti, Italy.
Background: Recurrent venous thromboembolism (VTE) is a common complication in patients with cancer-associated VTE. Limited data are available on treatment, particularly in patients receiving direct oral anticoagulants (DOACs). We aimed to evaluate current management strategies and outcomes in patients with cancer and recurrent VTE during treatment with low-molecular-weight heparin (LMWH) or DOACs.
View Article and Find Full Text PDFContraception
September 2025
Bayer Aktiengesellschaft, Wuppertal - Aprath, Germany.
Objective: This study aimed to validate the real-world performance of the MyIUS mobile-application algorithm in predicting bleeding intensity and regularity in levonorgestrel intrauterine device (LNG-IUD) 52 mg, 19.5 mg, and 13.5 mg users following device insertion.
View Article and Find Full Text PDF